BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12065876)

  • 21. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
    Giatromanolaki A; Sivridis E; Stathopoulos GP; Fountzilas G; Kalofonos HP; Tsamandas A; Vrettou E; Scopa C; Polychronidis A; Simopoulos K; Koukourakis MI
    Anticancer Res; 2001; 21(1A):253-9. PubMed ID: 11299743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma.
    Lazaris AC; Theodoropoulos GE; Anastassopoulos P; Nakopoulou L; Panoussopoulos D; Papadimitriou K
    Histol Histopathol; 1995 Jul; 10(3):661-8. PubMed ID: 7579815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 and mdm2 expression in colorectal carcinoma: a correlative analysis with clinical staging and histological parameters.
    Das P; Vaiphei K; Jain D; Wig JD
    Int J Surg Pathol; 2007 Oct; 15(4):335-45. PubMed ID: 17913939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Yu D; Agrawal S; Zhang R
    Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression.
    Dworakowska D; Jassem E; Jassem J; Karmoliński A; Dworakowski R; Wirth T; Gruchała M; Rynkiewicz A; Skokowski J; Yla-Herttuala S; Jaśkiewicz K; Czestochowska E
    J Cancer Res Clin Oncol; 2005 Sep; 131(9):617-23. PubMed ID: 16028106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer.
    Brett MC; Pickard M; Green B; Howel-Evans A; Smith D; Kinsella A; Poston G
    Eur J Surg Oncol; 1996 Apr; 22(2):182-5. PubMed ID: 8608838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abnormal expression of MDM2 in prostate carcinoma.
    Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
    Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas.
    Pagnano KB; Vassallo J; Lorand-Metze I; Costa FF; Saad ST
    Am J Hematol; 2001 Jun; 67(2):84-92. PubMed ID: 11343379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil.
    Aschele C; Debernardis D; Tunesi G; Maley F; Sobrero A
    Clin Cancer Res; 2000 Dec; 6(12):4797-802. PubMed ID: 11156237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
    Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
    J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy.
    Buglioni S; D'Agnano I; Vasselli S; Perrone Donnorso R; D'Angelo C; Brenna A; Benevolo M; Cosimelli M; Zupi G; Mottolese M
    Am J Clin Pathol; 2001 Sep; 116(3):360-8. PubMed ID: 11554164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer.
    Tominaga T; Iwahashi M; Takifuji K; Hotta T; Yokoyama S; Matsuda K; Higashiguchi T; Oku Y; Nasu T; Yamaue H
    Int J Cancer; 2010 Apr; 126(7):1691-701. PubMed ID: 19810096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations.
    Günther T; Schneider-Stock R; Häckel C; Kasper HU; Pross M; Hackelsberger A; Lippert H; Roessner A
    Mod Pathol; 2000 Jun; 13(6):621-6. PubMed ID: 10874665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population.
    Chaar I; Arfaoui TA; El Amine el HO; Mahmoud LB; Khiari M; Sammoud S; Lounis A; Amara S; Gharbi L; Hmida AB; Mzabi S; Bouraoui S
    Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):320-7. PubMed ID: 22266832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
    Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
    Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of the apoptotic index analysed jointly with selected cell cycle regulators and proliferation markers in non-small cell lung cancer.
    Dworakowska D; Jassem E; Jassem J; Karmoliński A; Lapiński M; Tomaszewski D; Rzyman W; Jaśkiewicz K; Sworczak K; Grossman AB
    Lung Cancer; 2009 Oct; 66(1):127-33. PubMed ID: 19200616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma.
    Coupland SE; Anastassiou G; Stang A; Schilling H; Anagnostopoulos I; Bornfeld N; Stein H
    J Pathol; 2000 Jun; 191(2):120-6. PubMed ID: 10861569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients.
    Backus HH; Dukers DF; van Groeningen CJ; Vos W; Bloemena E; Wouters D; van Riel JM; Smid K; Giaccone G; Pinedo HM; Peters GJ
    Ann Oncol; 2001 Feb; 12(2):209-16. PubMed ID: 11300326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
    Kozak MM; von Eyben R; Pai J; Vossler SR; Limaye M; Jayachandran P; Anderson EM; Shaffer JL; Longacre T; Pai RK; Koong AC; Chang DT
    J Clin Pathol; 2015 May; 68(5):341-5. PubMed ID: 25681512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma.
    Claudio PP; Zamparelli A; Garcia FU; Claudio L; Ammirati G; Farina A; Bovicelli A; Russo G; Giordano GG; McGinnis DE; Giordano A; Cardi G
    Clin Cancer Res; 2002 Jun; 8(6):1808-15. PubMed ID: 12060621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.